person · Reporting owner
GROENHUYSEN WILHELMUS CM
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Operating Officer | June 28, 2024 | August 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 28, 2024 · Filed August 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 252,290 |
Reported balance
After 2024-06-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-06-28 · Grant · Acquired 1,055 · Balance 252,290 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OptiNose, Inc.
Report date May 21, 2025 · Filed May 21, 2025
Section 16 reporting ended · disclosed 2025-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.60 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.70 · Expires 2033-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 3,566 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 2,133 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.10 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.75 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.00 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $337.50 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-05-21 · Disposition to issuer · Disposed 962 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.00 · Expires 2027-10-12 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-05-21 · Disposition to issuer · Disposed 1,925 · Balance 0 F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time'). F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 19, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Paratek Pharmaceuticals, Inc., a Delaware corporation ("Parent"), and Orca Merger Sub, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent upon consummation of the merger (the "Effective Time').
F2: At the Effective Time, each outstanding share of Common Stock was automatically converted into the right to receive (i) $9.00 in cash, without interest (the "Cash Consideration") and (ii) one contractual contingent value right ("CVR") per share representing the right to receive two contingent payments of up to $5.00 in cash upon achievement of specified milestones, as specified further in the CVR Agreement, by and among Parent and Equiniti Trust Company, LLC, as rights agent.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unexercised stock option, whether vested or unvested, was converted into the right to receive (i) an amount in cash, without interest, equal to the excess, if any of (A) the Cash Consideration over (B) the exercise price per share of such stock option; provided that, (1) each stock option with an exercise price per share that is greater than $14.00 (the sum of the Cash Consideration and the maximum amount payable under the CVR) was cancelled for no consideration and (2) each stock option with an exercise price per share that is greater than the amount of the Cash Consideration but less than $14.00 was canceled and converted into the right to receive one CVR with the amount payable pursuant to such CVR, if any, reduced by the amount by which the exercise price per share of such stock option exceeds the Cash Consideration).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2020 Filed Jan 25, 2020 00:11 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,515 | $98.11 | $148,632.11 |
DisclosureSEC source: 0001645113-20-000009 · wf-form4_157991104778037.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,343 F2 · price: On January 22, 2020, Mr. Groenhuysen sold 1,515 shares in multiple trades at prices ranging from $97.80 to $98.73. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 22, 2020 Filed Jan 25, 2020 00:11 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 1,515 | $7.03 | $10,650.45 |
DisclosureSEC source: 0001645113-20-000009 · wf-form4_157991104778037.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 21:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 164 | $52.58 | $8,623.28 |
DisclosureSEC source: 0001645113-20-000007 · wf-form4_157894995499763.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,343 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2019 through December 31, 2019. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2019. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,832 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · derivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,832 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 900 | $86.93 | $78,234.30 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F7 · price: On November 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 900 shares in multiple trades at prices ranging from $86.66 to $87.64. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,132 | $86.08 | $269,602.56 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,079 F6 · price: On November 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 3,132 shares in multiple trades at prices ranging from $85.65 to $86.63. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,800 | $85.35 | $153,633.60 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,211 F5 · price: On November 18, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,800 shares in multiple trades at prices ranging from $84.65 to $85.61. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,832 | $3.44 | $20,062.08 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · derivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,832 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,439 | $84.01 | $120,886.07 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F4 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,439 shares in multiple trades at prices ranging from $83.98 to $84.03. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 12,461 | $83.52 | $1,040,767.64 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,618 F3 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 12,461 shares in multiple trades at prices ranging from $82.98 to $83.98. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,100 | $82.53 | $503,439.10 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,079 F2 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 6,100 shares in multiple trades at prices ranging from $81.98 to $82.97. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:22 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001645113-19-000009 · wf-form4_157419854322991.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,407 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 27 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,979 Underlying: Ordinary Shares · 2,407 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 26 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,832 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,169 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 25 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,169 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 504 | $82.62 | $41,641.99 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 21 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F16 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 504 shares in multiple trades at prices ranging from $82.54 to $82.69. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,403 | $81.80 | $114,771.01 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 20 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,683 F15 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,403 shares in multiple trades at prices ranging from $81.46 to $82.44. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $80.96 | $40,478.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 19 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,086 F14 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 500 shares in multiple trades at prices ranging from $80.37 to $81.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,407 | $7.03 | $16,921.21 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 18 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,586 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,200 | $82.54 | $594,252.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 17 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F13 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 7,200 shares in multiple trades at prices ranging from $82.13 to $82.89. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,800 | $81.67 | $881,992.80 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 16 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,379 F12 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 10,800 shares in multiple trades at prices ranging from $81.13 to $82.12. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,000 | $80.78 | $161,556.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 15 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,179 F11 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,000 shares in multiple trades at prices ranging from $80.13 to $81.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 14 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,764 | $82.50 | $145,526.47 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 13 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F10 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 1,764 shares in multiple trades at prices ranging from $82.18 to $82.80. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,805 | $81.66 | $229,061.91 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,943 F9 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,805 shares in multiple trades at prices ranging from $81.14 to $82.11. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 600 | $80.68 | $48,409.20 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,748 F8 · price: On November 14, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 600 shares in multiple trades at prices ranging from $80.13 to $81.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,169 | $3.44 | $17,781.36 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 24 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,386 Underlying: Ordinary Shares · 10,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 23 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,832 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · derivative · entry 22 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,169 Underlying: Ordinary Shares · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F17 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,542 | $81.16 | $206,303.64 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F7 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,542 shares in multiple trades at prices ranging from $81.08 to $81.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,458 | $80.79 | $602,494.53 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,721 F6 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 7,458 shares in multiple trades at prices ranging from $80.06 to $81.06. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,332 | $81.13 | $513,683.50 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 6 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F5 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 6,332 shares in multiple trades at prices ranging from $81.01 to $81.36. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 13,668 | $80.72 | $1,103,239.96 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,511 F4 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 13,668 shares in multiple trades at prices ranging from $80.00 to $81.00. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,458 | $81.16 | $199,486.36 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F3 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 2,458 shares in multiple trades at prices ranging from $81.08 to $81.34. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,542 | $80.80 | $609,408.68 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,637 F2 · price: On November 13, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen, Mr. Groenhuysen sold 7,542 shares in multiple trades at prices ranging from $80.07 to $81.06. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:25 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $3.44 | $34,400.00 |
DisclosureSEC source: 0001645113-19-000008 · wf-form4_157385312184714.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Groenhuysen. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 18 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,386 Underlying: Ordinary Shares · 10,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 17 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,832 Underlying: Ordinary Shares · 20,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 16 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,169 Underlying: Ordinary Shares · 10,000 shares Expires 2021-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,000 | $80.01 | $800,050.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 12 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F5 · price: On November 12, 2019, Mr. Groenhuysen sold 10,000 shares in multiple trades at prices ranging from $80.00 to $80.09. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 11 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,000 | $80.19 | $1,603,740.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 10 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F4 · price: On November 12, 2019, Mr. Groenhuysen sold 20,000 shares in multiple trades at prices ranging from $80.00 to $80.22. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $3.44 | $68,800.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 9 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,000 | $80.30 | $803,020.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 8 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,179 F3 · price: On November 12, 2019, Mr. Groenhuysen sold 10,000 shares in multiple trades at prices ranging from $80.00 to $80.85. The price reported above reflects the weighted average sale price. Mr. Groenhuysen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $3.44 | $34,400.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · nonDerivative · entry 7 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:30 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,900 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000004 · wf-form4_157368059943557.xml · derivative · entry 15 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,386 Underlying: Ordinary Shares · 1,900 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options exercised were fully vested as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.